As of June 7, 2025, Strongbridge Biopharma plc (SBBP) reports a ROA (Return on Assets) of 18.70%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Strongbridge Biopharma plc's ROA (Return on Assets)
Over recent years, Strongbridge Biopharma plc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2020-12-31 | 18.70% |
| 2019-12-31 | -42.05% |
| 2018-12-31 | 18.70% |
| 2017-12-31 | -109.22% |
| 2016-12-31 | -35.35% |
This slight downward trend highlights how Strongbridge Biopharma plc manages its efficiency in using assets to generate earnings over time.
Comparing Strongbridge Biopharma plc's ROA (Return on Assets) to Peers
To better understand Strongbridge Biopharma plc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Strongbridge Biopharma plc (SBBP) | 18.70% |
| AcelRx Pharmaceuticals Inc (ACRX) | 100.55% |
| Zoetis Inc (ZTS) | 17.46% |
| Next Green Wave Holdings Inc (NGW.CN) | 17.05% |
| Merck & Co Inc (MRK) | 14.62% |
| Eli Lilly and Co (LLY) | 13.45% |
Compared to its competitors, Strongbridge Biopharma plc's ROA (Return on Assets) is among the highest compared to peers, demonstrating superior efficiency in generating earnings from assets.